Ibentatug

艾本妥塔单抗

Report date: 2023/12/29 10:37:05

Base Information

Drug NameIbentatug
Drug Alias Namea humanized immunoglobulin IgG1 antibody with a kappa light chain (LC) which has high selectivity and specificity for cancer-specific plectinZB-131
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionPlectin inhibitors
TargetsPlectin
Therapy Area/IndicationsSolid tumoursOvarian NeoplasmsBiliary Tract Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesZielbio Inc
China Registration ClassN/A

Develop Information

Active CompaniesZielbio Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursOvarian NeoplasmsBiliary Tract Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A